Abstract
Patients in the United States receive multiple forms of written information about their prescription medications. This pilot study was conducted to evaluate alternative formats of patient-directed written prescription information for four medications: cefaclor suspension, simvastatin tablets, albuterol inhaler, and capecitabine tablets. Fifty-four consumers evaluated this information using a 5-point satisfaction scale, responding to 10–12 questions, and participating in group discussion. Overall, consumers valued short, simple text, a question-answer format, a table layout, large font, adequate text spacing, bold type for emphasis, and easy-to-understand, actionable information that included impact statements on activities and lifestyle. This pilot study reveals that simplified prescription information with improved readability and reduced ambiguity may enhance consumer information retrieval and reinforce appropriate use of prescription medicines.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Steering Committee for the Collaborative Development of a Long- Range Action Plan for the Provision of Useful Prescription Medicine Information. Unpublished report submitted to the Secretary of the US Department of Health and Human Services. December 1996. https://doi.org/www.fda.gov/cder/offices/ods/keystone.pdf.
US Department of Health and Human Services. Food and Drug Administration. Guidance: useful written consumer medication information (CMI). July 2006. https://doi.org/www.fda.gov/CDER/GUI DANCE/7139fnl.htm.
Medication guides for prescription drug products. Code of Federal Regulations 2009. 21 CFR 208.
Patient package inserts for estrogens. Code of Federal Regulations 2009. 21 CFR 310.515.
Public Law 104–180. Title VI. Sec. 601. Effective medication guides. 110 Stat 1593(1996).
Kimberlin CL, Winterslein AG. Expert and consumer evaluation of consumer medication information 2008. Final report to the US Department of Health and Human Services and the Food and Drug Administration. November 4, 2008.
US Department of Health and Human Services. Food and Drug Administration. FDA’s strategic plan for risk communication. Unpublished report. Fall 2009. https://doi.org/www.fda.gov/downloads/About FDA/ReportsManualsForms/Reports/UCMI83683.pdf.
Schwartz LM, Woloshin S, Welch G, Using a drug facts box to communicate drug benefits and harms. Ann Intern Med. 2009:150:516–527.
Roche. U.S. prescribing information for Xeloda (capecitabine). April 2006. Nutley, NJ.
Merck & Co. Inc. U.S. prescribing information for Zocor (simvastatin), June 2008. Whitehouse Station, NI.
GlaxoSmithKline. U.S. prescribing information for Ventolin HFA (albuterol sulfate) inhalation aerosol. April 2008. Research Triangle Park. NC.
Ranbaxy Pharmaceuticals, Inc. U.S. prescribing information for cefaclor suspension. January 2008. Jacksonville, FL. Accessed via DailvMed, August 3, 2009.
Morrow D, Leirer V, Altieri P. List formats improve medication instructions for older adults. Educ Gerontol. 1995;21:151–166.
Morrow DG. Leirer VO, Andrassy JM, et al. The influence of list format and category headers on age differences in understanding medication instructions. Exp Aging Res. 1998;24:231–256.
Tai-Seale M, McGuire TG. Zhang W. Time allocation in primary care office visits, HSR: Health Serv Res. 2007;42:1871–1894.
Puspitasari HP, Aslani P, Krass 1. A review of counseling practices on prescription medicines in community pharmacies. Res Soc Admin Pharm. 2009;5:197–210.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Papay, J.I., Fritz, D., Cantu, T. et al. Assessment of a Simplified Format of Written Patient Prescription Drug Information. Ther Innov Regul Sci 44, 375–391 (2010). https://doi.org/10.1177/009286151004400403
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286151004400403